FXR agents such as OCA impact NASH pathology in mice via induction of FGF15, a human FGF19 ortholog, which acts on the liver to reduce the production of bile acids (44, 45). The gene discussed is FGF19; the disease is metabolic dysfunction-associated steatohepatitis.